Research workbench
Microcin C7 self immunity protein mccf in the wild type apo state
Analyse Microcin C7 self immunity protein mccf in the wild type apo state in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.
- PDB
- 3TLA
- Type
- protein
- Length
- 670 residues
- Chains
- 2
- Method
- x-ray diffraction
- Collection
- MolNFT v1 / PDB
- Contract
- 0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
- Owner
- 0x3396CDB397284571d12822B4ae1189a8E22AAAAA
- Molecule
- Mccf
- UniProt
- Q2KKH9
- Pockets
- 6 · best druggability 0.60
Structure
x-ray diffraction · 1 distinct chain · 31% helix, 23% strand (DSSP).
| Chain | Molecule | Type | Residues | Secondary structure | UniProt |
|---|---|---|---|---|---|
| A, B | Mccf | protein | 335 | 31% helix, 23% strand | Q2KKH9 |
Ligands and binding sites
- EDO · 1,2-ethanediol · additive · chains A
Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.
Pockets
6 pockets found on a 1 Å grid, 4 with a druggability of 0.5 or more.
| Volume (ų) | Druggability | Buriedness | Lining residues | Inside | |
|---|---|---|---|---|---|
| 1 | 85 | 0.60 | 0.88 | 20 | EDO |
| 2 | 292 | 0.57 | 0.77 | 43 | empty |
| 3 | 270 | 0.56 | 0.77 | 36 | empty |
| 4 | 93 | 0.55 | 0.85 | 25 | empty |
| 5 | 55 | 0.31 | 0.75 | 11 | empty |
Interfaces
1 interface between chains.
- A–B · 1886 Ų buried · 43 hydrogen bonds · protein-protein
Compared structures
- 3TLA · Microcin C7 self immunity protein MccF in the wild type APO state · the same entry in another collection · chain A against A, TM-score 1.00
Analyse
- Open in the research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides and crosslinks on the 3D structure
- Every structure of UniProt Q2KKH9
- Elsewhere: RCSB PDB 3TLA · PDBe 3TLA · UniProt Q2KKH9
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.